MedX Health Corporation has announced the appointment of Sylvain Desjeans as the company’s president and chief executive officer with immediate effect.
With more than 30 years of healthcare and pharmaceutical industry experience, Desjeans has served in successively senior roles at organizations such as Aspen Pharmacare (JSE:APN) Canada, Accucaps Industries Limited and Biovail Pharmaceuticals. He has a long track record of successfully executing large-scale growth plans and global product licensing initiatives.
Desjeans joined MedX on May 5, 2021, as chief revenue officer, and has been working on the company’s market opportunities, including the application of the MedX Dermsecure platform’s artificial intelligence features, as well as initiatives focussed on revenue generation.
READ: MedX Health strikes North American distribution deal with VidaCeuticals Health Products
The company said his appointment follows a comprehensive recruitment process led by the MedX board of directors.
“Sylvain brings extensive knowledge of, and experience in, the global medical technology market,” said Rob von der Porten, chairman of the MedX board of directors in a statement. “As a leader, he is exceptional at building sales, opening distribution channels and developing high-performing teams that deliver results, all of which are imperative for MedX to achieve our growth plans in Canada, the US and internationally.”
Desjeans commented: “I am honoured at this appointment, and I look forward to helping MedX realize its potential during a time of substantial growth for the Company. We’ve learned from the challenges of the COVID-19 pandemic that there is a strong need for increasing access and speed to healthcare for patients. I’m energized by the fact that our products are uniquely positioned to maintain a leadership position in this industry. Ultimately, our purpose at MedX is to save lives.”
MedX’s leading telemedicine platform allows healthcare practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments. As the world continues to navigate through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes.
Headquartered in Mississauga, Ontario, MedX is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology.
SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds.
These products are cleared by Health Canada, the US Food and Drug Administration (FDA), the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.
Contact the author at jon.hopkins@proactiveinvestors.com